<DOC>
	<DOCNO>NCT00500552</DOCNO>
	<brief_summary>Hypertrophic Cardiomyopathy ( HCM ) relatively common inherited heart muscle disease . Many patient experience symptom breathlessness , fatigue chest pain . These symptom always control current therapy . Recently investigator show drug call Perhexiline markedly improve exercise capacity symptoms patient heart failure . In proposal investigator wish test whether Perhexiline improve exercise capacity relieve symptom patient HCM</brief_summary>
	<brief_title>Perhexiline Therapy Patients With Hypertrophic Cardiomyopathy</brief_title>
	<detailed_description>Background : Hypertrophic cardiomyopathy ( HCM ) complex relatively common genetic cardiac disease common cause sudden cardiac death young people , include trained athlete . In recent study use vivo cardiac MR spectroscopy rest PCr/ATP ratio diminish patient sarcomeric HCM , indicate reduce energy availability . Importantly patient genotypic HCM yet hypertrophy similar degree impairment cardiac PCr/ATP ratio patient mark hypertrophy , imply disturbance may early feature disease simply due hypertrophy . In medically refractory patient obstruction , surgical myectomy alcohol septal ablation may effective . However patient non obstructive HCM symptom refractory standard drug therapy , therapeutic option ( apart cardiac transplant severe case ) . Recently , group show Perhexiline , antianginal agent oxygen-sparing metabolic effect increase efficiency energy production shift substrate utilisation free fatty acid towards glucose , highly effective improving symptom , exercise capacity ( Vo2max ) cardiac function patient systolic heart failure ischaemic non ischaemic aetiology . Hypothesis : The investigator postulate Perhexiline improve symptomatic status , peak oxygen consumption , rest exercise diastolic function associate improvement myocardial energetic status highly symptomatic medically refractory patient non obstructive HCM . Methods design : The study multi-centre randomise double blind placebo control trial . 50 patient meet entry criterion provide write informed consent recruit study . Patients recruit cardiomyopathy clinic London , Birmingham Oxford . The primary end point peak oxygen consumption ( Vo2max ) . Secondary end point rest myocardial energetics ( 31P Cardiac MR Spectroscopy ) , rest exercise diastolic function ( Myocardial Nuclear study ) , Symptomatic Status ( Minnesota questionnaire ) LV function ( Speckle Tracking Echo measurement ) . After investigation perform , subject randomise receive either 100 mg Perhexiline day placebo 3 month . Following completion three month therapy , investigation repeat .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<mesh_term>Perhexiline</mesh_term>
	<criteria>1 . Symptomatic Hypertrophic Cardiomyopathy patient 2 . Abnormal Peak VO2 3 . No significant LVOT obstruction rest ( gradient &lt; 30mmHg ) 4 . Sinus rhythm 1 . Abnormal LFT . 2 . Concomitant use amiodarone 3 . Preexisting evidence peripheral neuropathy . 4 . Women childbearing potential . 5 . Patients ICD 's exclude MR part study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Perhexiline</keyword>
	<keyword>Hypertrophic Cardiomyopathy</keyword>
</DOC>